BioRegenx, Inc. BRGX
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 93.54% | 93.30% | -285.45% | -173.53% | -- |
| Total Depreciation and Amortization | -95.63% | -96.62% | -62.83% | 11.77% | -- |
| Total Amortization of Deferred Charges | -97.99% | -95.36% | 30.24% | 1.21% | -- |
| Total Other Non-Cash Items | -94.42% | -94.34% | 607.35% | 249.34% | -- |
| Change in Net Operating Assets | -45.02% | -28.56% | 116.28% | 364.29% | -- |
| Cash from Operations | 115.26% | 112.00% | 92.46% | 99.79% | -- |
| Capital Expenditure | -- | 95.20% | 96.83% | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -100.00% | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,951.85% | -- | 76.60% | 76.60% | -- |
| Cash from Investing | -2,288.89% | 68.55% | 86.33% | 87.87% | -- |
| Total Debt Issued | -19.49% | -69.92% | -69.68% | -82.55% | -- |
| Total Debt Repaid | -288.35% | -137.34% | -40.46% | 33.85% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -104.49% | -92.51% | -92.70% | -95.55% | -- |
| Foreign Exchange rate Adjustments | 100.00% | -172.41% | 195.00% | -1,416.67% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.86% | 116.27% | -291.74% | 93.45% | -- |